ArticleThe American journal of pathology2006
Profiling bladder cancer using targeted antibody arrays.
Article in The American journal of pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 167 citations in OpenAlex.
- Seed protein electrophoresis in plant genetics: Commemorating the pioneering contributions of Prof. Chittaranjan Kole and team to the foundation of plant proteomics.The plant genome · 2025Review
- Strategies for the drug development of cancer therapeutics.Frontiers in pharmacology · 2025Review
- Proteomics and Its Current Application in Biomedical Area: Concise Review.TheScientificWorldJournal · 2024Review
- Screening of novel serum biomarkers for gastric cancer in coastal populations using a protein microarray.Cancer science · 2023Article
- TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology.Medical oncology (Northwood, London, England) · 2023Review
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- Proteomics technologies for cancer liquid biopsies.Molecular cancer · 2022Review
- c-Met: A Promising Therapeutic Target in Bladder Cancer.Cancer management and research · 2022Review
- Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Article
- c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression.Nature communications · 2019Article
- Serum biomarker panels for the diagnosis of gastric cancer.Cancer medicine · 2019Article
- Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.PloS one · 2016Article
- Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.Oncotarget · 2015Article
- Up-to-Date Applications of Microarrays and Their Way to Commercialization.Microarrays (Basel, Switzerland) · 2015Review
- Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Nature reviews. Cancer · 2015Review
- Article
- Met in urological cancers.Cancers · 2014Review
- Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder.Cancers · 2014Article
- Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.Journal of translational medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a common malignancy requiring a high degree of surveillance because of the frequent recurrences and the poor clinical outcome of invasive disease. To date, serum biomarkers for bladder cancer lack optimal sensitivity and specificity to assist in diagnosis and disease categorization. Here, we designed antibody arrays for bladder cancer by selecting antibodies against targets differentially expressed in bladder tumors. Serum protein profiles measured by an antibody array containing 254 antibodies discriminated bladder cancer patients from controls (n = 95) with a correct classification rate of 93.7%. A second independent antibody array containing 144 antibodies revealed that protein profiles provide predictive information by stratifying patients with bladder tumors (n = 37) based on their overall survival (P = 0.0479). In addition, serum proteins, such as c-met, that were top ranked at identifying bladder cancer patients were associated with pathological stage, tumor grade, and survival when validated by immunohistochemistry of tissue microarrays containing bladder tumors (n = 173). This study provides experimental evidence for the use of several integrated technologies strengthening the process of biomarker discovery. Serum protein profiles obtained by antibody arrays represent comprehensive means for bladder cancer diagnosis and clinical outcome stratification, which could potentially assist in selection of cancer patients who would benefit from early, individualized therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.